



ROFIN-SINAR TECHNOLOGIES

- PRESS RELEASE -

Contact: Thorsten Frauenpreiss
ROFIN-SINAR
+49-40-733-63-256

ROFIN-SINAR COMPLETES SALE OF MEDICAL LASER BUSINESS DIVISION TO WAVELIGHT

Plymouth, MI / Hamburg, Germany, October 8, 2001 – ROFIN-SINAR Technologies, Inc. (NASDAQ: RSTI), one of the world's leading developers and manufacturers of high-performance laser beam sources and laser-based system solutions, today announced that it completed, on October 5, 2001, the sale of the medical laser business segment of Carl Baasel Lasertechnik GmbH & Co. KG, Starnberg (a majority-owned subsidiary of Rofin-Sinar) to WaveLight Laser Technologie AG, Germany. In July 2001, the Company had signed a "Letter of Intent" to sell the medical laser business.

Under the terms of the agreement WaveLight Laser Technologie AG will acquire Carl Baasel Lasertechnik's medical laser business of laser systems for aesthetic surgical applications. Micro-applications such as fine cutting and welding or laser marking of surgical components are not part of this agreement. The integration of the medical laser business into WaveLight's corporate structure is expected to be fully accomplished by the end of this year. The location of the medical laser business will remain in Starnberg. Further details of the transaction were not disclosed.

Carl F. Baasel, founder and managing director of Carl Baasel Lasertechnik, commented: "This is an important step for both companies, as it will enable us to concentrate on our core business of laser micro and marking applications and system solutions for industrial materials processing in the current market environment. Our medical laser portfolio will augment WaveLight's existing business activities - thus, both companies will substantially strengthen their respective market positions."

"This purchase will strengthen our role as a full range supplier in the aesthetics business segment and fits perfectly into our growth strategy in this area," commented Max Reindl, founder and CEO of WaveLight Laser Technologie AG. "The acquisition of the medical laser business activities of Rofin will not only enhance our growth in the aesthetics business area, but also add to the growth of the whole company."

With operational headquarters in Plymouth, Michigan and Hamburg, Germany, Rofin-Sinar Technologies, Inc. designs, develops, engineers and manufactures laser sources and laser-based system solutions for a wide range of applications. With production facilities in the US, Germany, UK, Singapore and Japan, Rofin-Sinar is one of the world's leading developers and manufacturers of industrial lasers and currently has more than 14,000 laser units installed worldwide and serves more than 2,500 customers. Rofin-Sinar's shares trade on the NASDAQ National Market System under the symbol RSTI. Since July 2, 2001, Rofin-Sinar's common stock is also traded under the German Securities Identification Number 902 757 on the German Neuer Markt at the Frankfurt Stock Exchange. Additional information is available on Rofin-Sinar's home

page: <http://www.rofin.com>.

Certain information included in this press release is forward-looking and is subject to important risks and uncertainties that could cause actual results to differ. Actual results could differ materially based on numerous factors, including currency risk, competition, risk relating to sales growth in CO₂, diode, and Nd:YAG lasers, cyclicalities, conflicting patents and other intellectual property rights of third parties, potential infringement claims and future capital requirements. These forward looking statements represent the Company's best judgment as of the date of this release based in part on preliminary information and certain assumptions which management believes to be reasonable. The Company disclaims any obligation to update these forward-looking statements.

###